...
首页> 外文期刊>Clinical and experimental nephrology >Preprandial microemulsion cyclosporine administration is effective for patients with refractory nephrotic syndrome
【24h】

Preprandial microemulsion cyclosporine administration is effective for patients with refractory nephrotic syndrome

机译:餐前微乳环孢素治疗对难治性肾病综合征患者有效

获取原文
获取原文并翻译 | 示例
           

摘要

Background/Aims The present study evaluated the clinical efficacy and pharmacokinetics of microemulsion cyclosporine A (ME-CyA) with modification from postprandial to preprandial administration in adult patients with i refractory nephrotic syndrome.Methods We investigated 19 patients with refractory nephrotic syndrome who had been switched from the postprandial administration of ME-CyA to preprandial administration. The pharmacokinetics of ME-CyA were also evaluated before and 6 months after switching from postprandial to preprandial administration by serial measurement of the blood CyA concentration in 10 patients. Results This study showed that 16 of 19 patients (84%) displayed an improvement in their clinical condition or continued to maintain remission after switching from post-to preprandial administration. In particular among 14 patients with minimal change nephrotic syndrome (MCNS) in this study, 13 patients maintained or achieved remission under preprandial ME-CyA administration. Only three of 10 patients with postprandial administration showed a peak concentration> 500 ng/ml within 1-2 h after administration, while with preprandial administration, nine of 10 patients showed this good absorption profiles. This effectiveness of preprandial administration seems to be dependent on the improved pharmacokinetics with the increase of area under the curve from 0^ h (AUCo^.) and peak concentration. There were no statistical differences in the mean daily doses of ME-CyA between both administration periods. No ME-CyA-induced nephrotoxicity or other harmful events were encountered throughout the study.Conclusion The preprandial administration of ME-CyA results in a good pharmacokinetic profile and is useful for management of refractory nephrotic syndrome in adults, particularly in patients with MCNS.
机译:背景/目的本研究评估了成人i型难治性肾病综合征患者从餐后改为餐前使用微乳环孢菌素A(ME-CyA)的临床疗效和药代动力学。方法我们调查了19例已转换为难治性肾病综合征的患者。从ME-CyA的餐后管理到餐前管理。还通过连续测量10例患者的血液CyA浓度,评估了从餐后转为餐前和餐后6个月的ME-CyA的药代动力学。结果该研究表明,从餐后给药改为餐前给药后,19例患者中有16例(84%)表现出临床症状改善或继续维持缓解。在这项研究中,特别是在14例最小变化肾病综合征(MCNS)患者中,有13例在餐前ME-CyA给药后维持或达到了缓解。餐后给药的10名患者中只有3名在给药后1-2小时内显示峰值浓度> 500 ng / ml,而餐前给药的10名患者中有9名显示出良好的吸收曲线。餐前给药的这种有效性似乎取决于药物动力学的改善,曲线下面积从0 h(AUC 0)和峰值浓度增加。在两个给药期之间,ME-CyA的平均日剂量没有统计学差异。在整个研究过程中未遇到ME-CyA引起的肾毒性或其他有害事件。结论ME-CyA的餐前给药具有良好的药代动力学特征,可用于治疗成人难治性肾病综合征,尤其是MCNS患者。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号